Well, I guess I will just have to wait and see where the shorts take this. Sitting on cash and know that they will try to drive it down before the CC. Holding a nice position and feel really good about things but love to have trading shares. I do not underestimate the shorties.
I think a poison pill proposal would be a good thing to think over at this point. Would make me a lot happier as we go forward.
Damit, now I have to get up early Dsaur. Hope that feeling isn't something you ate.
If that were true we would be much higher. We are here because that is where the market values us. The pending P3 and dilution is one reason we are here and another is the P2 results. Although they were good, I know the market was looking for much better. I can look back at the three week plunge after the results were made public and it was only Dr. Kim's huge buy that helped slow it down. Roche put the last nail in the box and we don't really know the reason. We have a lot of doubt and uncertainty to overcome and that will take Data and Partnerships. The bar was raised quite a bit by investors and management by indicating VG-3100 was the low hanging fruit and we were looking for results over 60% as was the street.
All that being said, we had great results and the treatment for CIN 1,2,3, still leaves a vast market for our vaccine both pre and post treatment. This will get acceptance in due time and may get fast tracked if we are lucky, but I think the recognition will come from the Ebola results. JMHO
PPS will hit the twos for sure without support from AT and gang. They didn't want to talk about earnings and will sit back and watch the pps provide op after op to buy. As good as the picture is for MVIS the street knows Tokman is in the corner of the shorts. A little help from the CFO would of done wonders for us, but it is the usual pop and drop for long shareholders here. GET A PAIR BOYS! This has been far too easy for years now.
Should be almost all positive. It's been negative for ten years now. We existed on promises and now we have a real product. Granted it is an entry level product but it is getting rave reviews and will get better. Just scratched the surface in my book.
Just happy to have a product in the wild at this point. Happy the reviews are what our guy indicated at CES. Crawl, walk, run, we are moving.